Patient characteristics and leukemia features at diagnosis in the validation (iBFM-FN) cohort
| Variable . | Validation cohort . | P value . | ||||
|---|---|---|---|---|---|---|
| Total . | CD371pos . | CD371neg . | ||||
| n . | n . | % . | n . | % . | ||
| Total | 969 | 84 | 8.7 | 885 | 91.3 | |
| Age (y), median | 5.1 | 9.2 | 4.6 | |||
| Sex | .286 | |||||
| Male | 516 | 51 | 60.7 | 465 | 54.6 | |
| Female | 419 | 33 | 39.3 | 386 | 45.4 | |
| NA | 34 | 0 | 34 | — | ||
| Fusion genes | ||||||
| ETV6::RUNX1 | 208 | 0 | 0.0 | 208 | 23.5 | < .001 |
| TCF3::PBX1 | 27 | 0 | 0.0 | 27 | 2.7 | .152 |
| KMT2A::AFF1 | 5 | 2 | 2.4 | 3 | 0.4 | .063 |
| Immunophenotype at diagnosis (EGIL) | < .001 | |||||
| B-I ALL | 23 | 7 | 8.4 | 16 | 1.8 | |
| B-II ALL | 703 | 64 | 77.1 | 639 | 72.6 | |
| B-III ALL | 232 | 12 | 14.5 | 220 | 25.0 | |
| B-IV (non Burkitt) | 5 | 0 | 5 | 0.6 | ||
| NA | 6 | 1 | — | 5 | — | |
| Ambiguous leukemia | ||||||
| BAL (EGIL) | 27 | 6 | 7.1 | 21 | 2.4 | .006 |
| MPAL (WHO) | 32 | 4 | 4.6 | 28 | 3.2 | .514 |
| Variable . | Validation cohort . | P value . | ||||
|---|---|---|---|---|---|---|
| Total . | CD371pos . | CD371neg . | ||||
| n . | n . | % . | n . | % . | ||
| Total | 969 | 84 | 8.7 | 885 | 91.3 | |
| Age (y), median | 5.1 | 9.2 | 4.6 | |||
| Sex | .286 | |||||
| Male | 516 | 51 | 60.7 | 465 | 54.6 | |
| Female | 419 | 33 | 39.3 | 386 | 45.4 | |
| NA | 34 | 0 | 34 | — | ||
| Fusion genes | ||||||
| ETV6::RUNX1 | 208 | 0 | 0.0 | 208 | 23.5 | < .001 |
| TCF3::PBX1 | 27 | 0 | 0.0 | 27 | 2.7 | .152 |
| KMT2A::AFF1 | 5 | 2 | 2.4 | 3 | 0.4 | .063 |
| Immunophenotype at diagnosis (EGIL) | < .001 | |||||
| B-I ALL | 23 | 7 | 8.4 | 16 | 1.8 | |
| B-II ALL | 703 | 64 | 77.1 | 639 | 72.6 | |
| B-III ALL | 232 | 12 | 14.5 | 220 | 25.0 | |
| B-IV (non Burkitt) | 5 | 0 | 5 | 0.6 | ||
| NA | 6 | 1 | — | 5 | — | |
| Ambiguous leukemia | ||||||
| BAL (EGIL) | 27 | 6 | 7.1 | 21 | 2.4 | .006 |
| MPAL (WHO) | 32 | 4 | 4.6 | 28 | 3.2 | .514 |
Bold value corresponds to P < .05.
BAL, biphenotypic acute leukemia; MPAL, mixed-phenotype acute leukemia; WHO, World Health Organization.